The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Local oestrogen for vaginal atrophy in postmenopausal women
Open accessAbstract
BACKGROUND: Vaginal atrophy is a frequent complaint of postmenopausal women; symptoms include vaginal dryness, itching, discomfort and painful intercourse. Systemic treatment for these symptoms in the form of oral hormone replacement therapy is not always necessary. An alternative choice is oestrogenic preparations administered vaginally (in the form of creams, pessaries, tablets and the oestradiol-releasing ring). OBJECTIVES: The objective of this review was to compare the effectiveness, safety and acceptability of oestrogenic preparations for women who suffer from vaginal atrophy. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Group Register of trials (searched January 2006), The Cochrane Library (2006,Issue 2), MEDLINE (1966 to January 2006), EMBASE (1980 to January 2006), Current Contents (1993 to January 2006, Biological Abstracts (1969 to 2006), Social Sciences Index (1980 to January 2006), PsycINFO (1972 to February 2006), CINAHL (1982 to January 2006) and reference list of articles. We also contacted manufacturers and researchers in the field. SELECTION CRITERIA: The inclusion criteria were randomised comparisons of oestrogenic preparations administered intravaginally in postmenopausal women for the treatment of symptoms resulting from vaginal atrophy or vaginitis. DATA COLLECTION AND ANALYSIS: Thirty-seven trials were identified: of these 18 were excluded. Included trials were assessed for quality and two reviewer authors extracted data independently. The ratios for dichotomous outcomes and means for continuous outcomes were calculated. The outcomes analysed were categorised under the headings of: efficacy, safety and acceptability. MAIN RESULTS: Nineteen trials with 4162 women were included in this review. The overall quality of the studies was good, although not all trials measured the same outcomes. All trials measured efficacy, with various outcome measures. When comparing the efficacy of different oestrogenic preparations (in the form of creams, pessaries, tablets and the oestradiol-releasing vaginal ring) in relieving the symptoms of vaginal atrophy, results indicated significant findings favouring the cream, ring, and tablets when compared to placebo and non-hormonal gel. Fourteen trials compared safety. Four looked at hyperplasia, four looked at endometrial overstimulation and seven looked at adverse effects. One trial showed significant adverse effects of the cream (conjugated equine oestrogen) when compared to tablets (oestradiol) which included uterine bleeding, breast pain and perineal pain (1 RCT; OR 0.18, 95% CI 0.07 to 0.50). Two trials showed significant endometrial overstimulation as evaluated by a progestagen challenge test with the cream (conjugated equine oestrogen) group when compared to the ring (OR 0.29, 95% CI 0.11 to 0.78). Although not statistically significant there was a 2% incidence of simple hyperplasia in the ring group when compared to the cream (conjugated equine oestrogen) and 4% incidence of hyperplasia (one simple, one complex) in the cream group (conjugated equine oestrogen) when compared to the tablet (oestradiol). Eleven studies compared acceptability to the participants by comparing: comfort of product use, ease of use, overall product rating, delivery system and satisfaction. Results showed a significant preference for the oestradiol-releasing vaginal ring. AUTHORS' CONCLUSIONS: Creams, pessaries, tablets and the oestradiol vaginal ring appeared to be equally effective for the symptoms of vaginal atrophy. One trial found significant side effects following cream (conjugated equine oestrogen) administration when compared to tablets causing uterine bleeding, breast pain and perineal pain. Another trial found significant endometrial overstimulation following use of the cream (conjugated equine oestrogen) when compared to the ring. As a treatment choice women appeared to favour the oestradiol-releasing vaginal ring for ease of use, comfort of product and overall satisfaction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oestrogen Therapy and the Menopausal Syndrome
CAMPBELL, S., & WHITEHEAD, M. (1977) · Clinics in Obstetrics and Gynaecology · doi:10.1016/s0306-3356(21)00374-5 · Cited by 539
Prevalence of Genitourinary Symptoms in the Late Menopause
Iosif, C. S., & Bekassy, Z. (1984) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.3109/00016348409155509 · Cited by 304
Bygdeman, M., & Swahn, M. L. (1996) · Maturitas · doi:10.1016/0378-5122(95)00955-8 · Cited by 299
Comparative study: Replens versus local estrogen in menopausal women
Nachtigall, L. E. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56474-7 · Cited by 229
Vaginal pH as a marker for bacterial pathogens and menopausal status
Caillouette, J. C., Sharp, C. F., Zimmerman, G. J., & Roy, S. (1997) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(97)70345-4 · Cited by 189
Rioux, J. E., Devlin, C. M., Gelfand, M. M., Steinberg, W. M., & Hepburn, D. S. (2000) · Menopause · doi:10.1097/00042192-200007030-00005 · Cited by 167
The vaginal epithelium in the postmenopause — cytology, histology and pH as methods of assessment
Nilsson, K., Risberg, B., & Heimer, G. (1995) · Maturitas · doi:10.1016/0378-5122(94)00863-3 · Cited by 159
Henriksson, L., Stjernquist, M., Boquist, L., et al. (1996) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(96)70378-2 · Cited by 145
Local estrogen treatment in patients with urogenital symptoms
Šimunić, V., Banović, I., Ciglar, S., Jeren, L., Baldani, D. P., & Šprem, M. (2003) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(03)00200-5 · Cited by 144
Eriksen, P. S., & Rasmussen, H. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90059-8 · Cited by 139
Cited by
ESHRE Guideline: management of women with premature ovarian insufficiency
(2016) · Human Reproduction · doi:10.1093/humrep/dew027 · Cited by 1,555
The 2012 Hormone Therapy Position Statement of The North American Menopause Society
(2012) · Menopause · doi:10.1097/gme.0b013e31824b970a · Cited by 785
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Local oestrogen for vaginal atrophy in postmenopausal women
Lethaby, A., Ayeleke, R. O., & Roberts, H. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001500.pub3 · Cited by 601
Self-citationLong term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Self-citationMac Bride, M. B., Rhodes, D. J., & Shuster, L. T. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0413 · Cited by 444
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
Self-citationAssociation between the vaginal microbiota, menopause status, and signs of vulvovaginal atrophy
Brotman, R. M., Shardell, M. D., Gajer, P., Fadrosh, D., Chang, K., Silver, M. I., Viscidi, R. P., Burke, A. E., Ravel, J., & Gravitt, P. E. (2014) · Menopause · doi:10.1097/gme.0b013e3182a4690b · Cited by 391
Takahashi, T. A., & Johnson, K. M. (2015) · Medical Clinics of North America · doi:10.1016/j.mcna.2015.01.006 · Cited by 355
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women
Perrotta, C., Aznar, M., Mejia, R., Albert, X., & Ng, C. W. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005131.pub2 · Cited by 350
Long term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub4 · Cited by 278
Self-citationHamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141
Metadata
- Authors
- Suckling, J. A., Kennedy, R., Lethaby, A., & Roberts, H.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-10-18
- Issue
- 4
- Pages
- CD001500-CD001500
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4246731109
- Cited by
- 359
- References
- 36
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.